Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors

An Open-label Phase 2 Study of AMG 706 in Japanese Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs) Who Developed Progressive Disease or Relapsed While on Imatinib Mesylate

The purpose of the study is to evaluate the safety and efficacy of AMG 706 in patients with gastrointestinal stromal tumor that have not been controlled while taking imatinib mesylate.

Inclusion Criteria:

• Diagnosis of histological confirmed GIST
• Had prior imatinib mesylate therapy
• Has at least 1 measurable leasion by modified RECIST

Exclusion Criteria:

• Central nervous system tumor involvement requiring treatment
• History of myocardial infraction
• Uncontrolled hypertension